No Surprises in Genzyme's Trial of Oral MS Drug Aubagio
By Cormac Sheridan
Wednesday, June 6, 2012
Genzyme Corp.'s once-daily oral multiple sclerosis drug Aubagio (teriflunomide) hit the two main clinical endpoints in a confirmatory pivotal Phase III trial: an annualized reduction in relapse rate and a reduction in the risk of sustained accumulation of disability.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.